How to Read Peptide Research: Understanding Study Design, Animal vs Human Dosing, and Effect Sizes

Reading peptide research requires more than scanning an abstract for positive results. The peptide literature spans a wide range of evidence quality, from robust multi-centre randomised controlled trials to single-arm pilot studies and preclinical animal work. Knowing how to distinguish strong evidence from preliminary findings is essential for anyone evaluating what the science actually supports. This guide covers the core skills: appraising study design, understanding dose translation between species, and interpreting effect sizes in context.

Study Design Hierarchy: Why Not All Evidence Is Equal

The strength of a scientific finding depends heavily on how the study was designed. In peptide research, the most commonly encountered designs include in vitro (cell culture) experiments, in vivo animal models, open-label human trials, and double-blind randomised controlled trials (RCTs).

Most published peptide studies are preclinical, conducted in rodent models or cell lines. Preclinical animal studies make up the majority of the published evidence base for many peptides discussed online, including BPC-157 and Thymosin Beta-4. A positive result in a mouse model does not confirm that the same effect will occur in humans. It indicates biological plausibility and justifies further investigation. The Peptide Register's peptide profiles categorise the available evidence by study type, making it easier to see at a glance whether a given peptide's claims rest on human data or animal-only findings.

Among human studies, the gold standard remains the double-blind, placebo-controlled RCT. Open-label studies, where both researchers and participants know what treatment is being administered, are more susceptible to placebo effects and observer bias. Case reports and case series, while sometimes informative, represent the lowest tier of clinical evidence. Many peptide studies reporting positive outcomes in humans have sample sizes under 50 participants, which limits statistical power and generalisability.

Translating Animal Doses to Human-Equivalent Doses

One of the most common errors in interpreting peptide research is reading a dose used in a mouse study and assuming it applies directly to humans. Animal-to-human dose conversion requires allometric scaling, which accounts for differences in body surface area, metabolic rate, and clearance between species. The FDA guidance document on estimating safe starting doses recommends using body surface area normalisation rather than simple body weight conversion. A dose of 1 mg/kg in a mouse does not translate to 1 mg/kg in a human. The standard FDA conversion factor from mouse to human is approximately 0.081, meaning a 1 mg/kg mouse dose corresponds to roughly 0.081 mg/kg in a human. This conversion factor is an approximation and does not account for species-specific differences in peptide metabolism, receptor affinity, or bioavailability.

Delivery route also affects how doses translate. Subcutaneous injection, intraperitoneal injection (common in rodents but rarely used in humans), and oral delivery each produce different pharmacokinetic profiles. Our overview of peptide bioavailability across delivery routes explains why the same nominal dose can produce very different plasma concentrations depending on how it is administered.

Interpreting Effect Sizes and Statistical Significance

A statistically significant result is not necessarily a clinically meaningful one. Statistical significance (typically p < 0.05) tells you that an observed difference is unlikely to be due to chance alone, but it says nothing about the magnitude of the effect. Effect size measures, such as Cohen's d for mean differences or relative risk ratios for binary outcomes, provide that context.

Cohen's d values are conventionally interpreted as small (0.2), medium (0.5), or large (0.8), though what counts as clinically relevant depends on the specific outcome being measured. In peptide research, many reported effect sizes come from small studies where confidence intervals are wide. Wide confidence intervals in small peptide studies mean the true effect could range from negligible to very large, making definitive conclusions premature.

It is also important to check whether studies report intention-to-treat analyses or per-protocol analyses. Per-protocol analyses exclude participants who dropped out or did not complete the study, which can inflate apparent treatment effects. Selective outcome reporting, where researchers highlight positive secondary endpoints while downplaying null primary endpoints, is another issue to watch for.

Red Flags and Critical Appraisal Checklist

When evaluating any peptide study, consider these questions: Was the study conducted in animals or humans? If in humans, was it blinded and placebo-controlled? What was the sample size, and was it powered to detect the claimed effect? Has the finding been independently replicated? Were conflicts of interest disclosed?

Studies funded by peptide manufacturers without independent replication warrant additional scrutiny. A single positive study, even a well-designed one, does not constitute settled science. Replication by independent research groups remains the benchmark for confidence in any finding.

The Peptide Register exists as an independent reference precisely because the gap between what the research shows and what online communities claim can be substantial. For broader context on how regulatory bodies evaluate peptide evidence, see our overview of peptide safety research and known risks. Critical reading skills are the best tool any researcher or clinician has for separating signal from noise in a rapidly expanding but often preliminary evidence base.